Efficacy News and Research

RSS
Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Study finds higher readmission rates for same-day total joint replacement surgery

Study finds higher readmission rates for same-day total joint replacement surgery

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

Researchers find effective strategy to eliminate cancer stem-like cells

Researchers find effective strategy to eliminate cancer stem-like cells

FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

Investigators urge drug regulators to provide clear evidence on statins’ side effects

Investigators urge drug regulators to provide clear evidence on statins’ side effects

Notre Dame biologists awarded $23M research grant to prevent malaria and dengue fever

Notre Dame biologists awarded $23M research grant to prevent malaria and dengue fever

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Study finds comparable outcomes for two commonly used procedures to treat pelvic organ prolapse

Study finds comparable outcomes for two commonly used procedures to treat pelvic organ prolapse

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.